Eli Lilly Might Be the Next Stock I Buy | LLY Stock Analysis
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 26 Sept 2026, 11:45 UTC
- Recorded by Tahlil Plus
- 26 Sept 2026, 15:48 UTC
AI-generated source summary
Eli Lilly and Company (LLY) has demonstrated exceptional financial performance, driven by its weight-loss treatments. Revenue has surged dramatically, with a nearly 10x increase in less than 10 years, reaching $79.67B in the trailing twelve months. Operating margins have also seen unprecedented growth, climbing to a record high of 49.72% from 15% in 2017. This signifies a significant improvement in profitability. The company is strategically investing heavily in research and development, spending a larger percentage of its revenue compared to competitors like Novo Nordisk and Pfizer. This R&D focus is expected to yield new treatments, potentially leading to continued sales growth and market share gains. The current forward price-to-earnings ratio of 24.21 suggests the stock may be undervalued, trading towards the lower end of its historical valuation metrics. Based on the current market price of $1,157.27, an intrinsic value per share of $1,494.84 suggests an upside potential of approximately 30% over the next 12-18 months, indicating a strong buy opportunity.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.